Top Ten most popular articles on Pharmafile.com this week
November 13, 2020Medical Communications
The top ten news stories this week focus on COVID-19 vaccines, with clinical trial participants who received the Pfizer/BioNTech coronavirus …
AstraZeneca’s Calquence fails to improve survival rates in coronavirus patients
November 12, 2020Business Services AZ, AstraZeneca, Calquence
AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised with COVID-19. Calquence (acalabrutinib) is …
NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura
November 12, 2020Sales and Marketing NHS, NICE, Sanofi, pharma
Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …
Pfizer CEO cashes in shares for $5.6m following strong Phase 3 COVID-19 vaccine data
November 12, 2020Sales and Marketing COVID-19, Pfizer, Vaccine, pharma
With the news that Pfizer and BioNTech’s COVID-19 vaccine candidate demonstrated 90% efficacy in a Phase 3 interim analysis, it …
COVID-19 increases the risk of developing psychiatric disorders, new study says
November 12, 2020Business Services
People who are infected with COVID-19 are at higher risk of developing depression, insomnia and anxiety for the first time, …
Pfizer/BioNTech vaccine side effects feel like a “severe hangover”
November 12, 2020Business Services COVID, Vaccine, coronavirus
Clinical trial participants receiving the Pfizer/BioNTech coronavirus vaccine have said it created side effects that felt similar to a “severe …
First interim Phase 3 data shows promise for Russia’s Sputnik V COVID-19 vaccine
November 11, 2020Research and Development COVID-19, Russia, Sputnik V, Vaccine
The first interim Phase 3 data for Russia’s Sputnik V COVID-19 vaccine have been released by the Gamaleya Research Center …
Head of UK vaccine taskforce grilled over government investment into her private equity firm
November 11, 2020Research and Development COVID, UK COVID, coronavirus
Kate Bingham, the Head of the British Government’s vaccine taskforce, is facing further questions over a conflict of interest as …
CureVac’s COVID-19 vaccine generates immune responses at Phase 1
November 11, 2020Research and Development COVID-19, CureVac, pharma
German biopharma firm CureVac has unveiled interim analysis data from a Phase1 study of its messenger RNA (mRNA) COVID-19 vaccine, CVnCoV, …
Hotels, gyms and restaurants carry highest COVID-19 spread risk, new study says
November 11, 2020Research and Development COVID, coronavirus
Reopening hotels, gyms and restaurants carries the highest risk of spreading coronavirus, according to a new study.
Pharmafile.com’s weekly COVID-19 news round-up
November 11, 2020Research and Development
The COVID-19 news this week focuses on vaccines, with AstraZeneca committing to an agreement to deliver 22 million doses of …
Pfizer and BioNTech’s COVID-19 vaccine shows 90% efficacy in interim analysis
November 10, 2020Manufacturing and Production, Research and Development BioNTech, COVID-19, Pfizer, Vaccine
Pfizer and BioNTech have ignited a wave of hope with the announcement of positive Phase 3 data demonstrating that their …
NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia
November 10, 2020Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax
NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …
Scottish Medicines Consortium greenlights Nubeqa for prostate cancer
November 10, 2020Manufacturing and Production, Sales and Marketing
The Scottish Medicines Consortium has approved Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are …
FDA grants Emergency Use Authorization to Eli Lilly’s antibody drug to treat COVID-19
November 10, 2020Manufacturing and Production
The FDA has granted Emergency Use Authorization (EUA) to Eli Lilly’s antibody drug bamlanivimab for the treatment of COVID-19 patients …
Sinovac COVID-19 trial suspended in Brazil due to severe adverse event
November 10, 2020Manufacturing and Production Brazil, COVID, COVID Vaccine, coronavirus
Brazil’s health regulator Anvisa has suspended a clinical trial for China’s Sinovac coronavirus vaccine due to the occurrence of a …
Argentina secures 22 million COVID-19 vaccine doses from AstraZeneca and Oxford Uni
November 9, 2020Manufacturing and Production, Sales and Marketing Argentina, AstraZeneca, COVID-19, Vaccine
AstraZeneca has committed to an agreement to deliver 22 million doses of its COVID-19 vaccine candidate, co-developed in partnership with …
AstraZeneca’s Brilinta combo reduces rate of disabling stroke or death in stroke patients, according to Phase 3 data
November 9, 2020Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma
AstraZeneca has unveiled new Phase 3 data for Brilinta (ticagrelor) as a treatment for patients who have suffered an acute …
Head of UK’s COVID-19 vaccine taskforce faces questions over biotech fund
November 9, 2020Sales and Marketing COVID, COVID-19, vaccines
Kate Bingham, the head of the British Government’s vaccine taskforce, faces scrutiny after it was revealed her venture capital firm …
FDA approves Nightware app on Apple Watch to treat sleep disturbances
November 9, 2020Sales and Marketing
The FDA has authorised the marketing of Nightware, a digital therapeutic application for the Apple Watch, in treating sleep disturbances. …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
